Treatment-Resistant Depression

Over 30% of Americans with major depressive disorder live with treatment-resistant depression (TRD), meaning their symptoms don’t improve with standard treatments. Hudson Specialty Care Spravato in Cliffside Park, Elizabeth, Edison, New Jersey, and New York City, Manhattan, Brooklyn offers in-office administration of SPRAVATO®, a prescription nasal spray containing esketamine, for adults diagnosed with TRD. While we do not provide counseling or ongoing psychiatric care, our team works with you and your mental health provider to deliver this FDA-approved treatment in a safe, supportive environment. Call the office or book online today to learn more about SPRAVATO® as an option for treatment-resistant depression.

What is treatment-resistant depression?

Treatment-resistant depression is a form of major depressive disorder (MDD) diagnosed when symptoms don’t improve after trying at least two antidepressant medications at adequate doses and durations. This can be discouraging, but it doesn’t mean there’s no hope—it often means a different treatment approach is needed.

What are the symptoms of treatment-resistant depression?

TRD shares the same symptoms as major depression, which may include:

• Persistent sadness or low mood
• Loss of interest in activities you once enjoyed
• Fatigue or low energy
• Sleeping too much or too little
• Appetite or weight changes
• Trouble concentrating
• Feelings of worthlessness or guilt
• Thoughts of death or suicide
  

With TRD, these symptoms continue despite standard treatment. In some cases, they may be more severe, chronic, or quick to return after initial improvement.

What causes treatment-resistant depression?

Possible contributing factors include:

• Biology and genetics: Differences in brain chemistry and metabolism may affect how medications work for you.
• Underlying medical conditions: Issues like thyroid disorders, chronic pain, or substance use can make depression harder to treat.
• Incorrect diagnosis: Depression may be part of another condition, such as bipolar disorder or PTSD, requiring a different treatment approach.
• Psychosocial factors: Chronic stress, trauma, or lack of social support can affect treatment response.
  

TRD isn’t about “resisting” treatment—it’s about finding a more tailored, evidence-based option.

How does Hudson Specialty Care Spravato help?

If you have TRD, SPRAVATO® may be recommended by your mental health provider as part of your care plan. Our role is to provide this treatment in-office, following all safety guidelines and monitoring you closely throughout each session.

SPRAVATO® is FDA-approved for TRD and works differently from traditional antidepressants by targeting NMDA receptors in the brain. Many patients experience relief within hours to days, making it a breakthrough option when other medications have failed.

Sessions are scheduled on a set protocol—usually twice weekly for the first month—then tapered based on your progress. You’ll self-administer the nasal spray under supervision, followed by a two-hour observation period to ensure safety and comfort.

If you’ve been diagnosed with treatment-resistant depression and are exploring SPRAVATO®, contact Hudson Specialty Spravato today to schedule your consultation and begin a new chapter in your care.